Erik Anders Kronström
Directeur des opérations chez INFANT BACTERIAL THERAPEUTICS AB
Fortune : 102 530 $ au 30/06/2024
Profil
Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/05/2024 | 11 194 ( 0,09% ) | 102 530 $ | 30/06/2024 |
Postes actifs de Erik Anders Kronström
| Sociétés | Poste | Début |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Directeur des opérations | 01/01/2018 |
Anciens postes connus de Erik Anders Kronström
| Sociétés | Poste | Fin |
|---|---|---|
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Directeur Général | - |
Formation de Erik Anders Kronström
| Royal Institute of Technology | Graduate Degree |
| Warwick Business School | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
